Table of Contents Author Guidelines Submit a Manuscript
Erratum

An erratum for this article has been published. To view the erratum, please click here.

BioMed Research International
Volume 2014, Article ID 616405, 14 pages
http://dx.doi.org/10.1155/2014/616405
Review Article

Preventive Strategies against Bleeding due to Nonvitamin K Antagonist Oral Anticoagulants

1Department of Anesthesiology, CHU Dinant-Godinne UCL Namur, Namur Thrombosis and Hemostasis Center (NTHC), NAmur Research Institute of Life Sciences (NARILIS), 5530 Yvoir, Belgium
2Department of Pharmacy, Namur Thrombosis and Hemostasis Center (NTHC), NAmur Research Institute of Life Sciences (NARILIS), University of Namur, 5000 Namur, Belgium
3Department of Hematology, CHU Dinant-Godinne UCL Namur, Namur Thrombosis and Hemostasis Center (NTHC), NAmur Research Institute of Life Sciences (NARILIS), 5530 Yvoir, Belgium
4Department of Internal Medicine, CHU Dinant-Godinne UCL Namur, Namur Thrombosis and Hemostasis Center (NTHC), NAmur Research Institute of Life Sciences (NARILIS), 5530 Yvoir, Belgium
5Department of Pharmacy, CHU Dinant-Godinne UCL Namur, Namur Thrombosis and Hemostasis Center (NTHC), NAmur Research Institute of Life Sciences (NARILIS), 5530 Yvoir, Belgium
6Université Catholique de Louvain, Louvain Drug Research Institute, Clinical Pharmacy Research Group, 1200 Brussels, Belgium
7Hematology Laboratory, CHU Dinant-Godinne UCL Namur, Namur Thrombosis and Hemostasis Center (NTHC), NAmur Research Institute of Life Sciences (NARILIS), 5530 Yvoir, Belgium

Received 28 February 2014; Accepted 14 April 2014; Published 16 June 2014

Academic Editor: Helen Mani

Copyright © 2014 Lessire Sarah et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. S. Husted, R. De Caterina, F. Andreotti et al., “Non-vitamin K antagonist oral anticoagulants (NOACs): no longer new or novel,” Journal of Thrombosis and Haemostasis, vol. 111, no. 5, 2014. View at Google Scholar
  2. M. R. Lassen, A. Gallus, G. E. Raskob, G. Pineo, D. Chen, and L. M. Ramirez, “Apixaban versus enoxaparin for thromboprophylaxis after hip replacement,” The New England Journal of Medicine, vol. 363, no. 26, pp. 2487–2498, 2010. View at Publisher · View at Google Scholar · View at Scopus
  3. M. R. Lassen, G. E. Raskob, A. Gallus, G. Pineo, D. Chen, and P. Hornick, “Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trial,” The Lancet, vol. 375, no. 9717, pp. 807–815, 2010. View at Publisher · View at Google Scholar · View at Scopus
  4. M. R. Lassen, G. E. Raskob, A. Gallus, G. Pineo, D. Chen, and R. J. Portman, “Apixaban or enoxaparin for thromboprophylaxis after knee replacement,” The New England Journal of Medicine, vol. 361, no. 6, pp. 594–604, 2009. View at Publisher · View at Google Scholar · View at Scopus
  5. B. I. Eriksson, O. E. Dahl, M. H. Huo et al., “Oral dabigatran versus enoxaparin for thromboprophylaxis after primary total hip arthroplasty (RE-NOVATE II): a randomised, double-blind, non-inferiority trial,” Thrombosis and Haemostasis, vol. 105, no. 4, pp. 721–729, 2011. View at Publisher · View at Google Scholar · View at Scopus
  6. B. I. Eriksson, O. E. Dahl, N. Rosencher et al., “Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial,” Journal of Thrombosis and Haemostasis, vol. 5, no. 11, pp. 2178–2185, 2007. View at Publisher · View at Google Scholar · View at Scopus
  7. B. I. Eriksson, O. E. Dahl, N. Rosencher et al., “Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial,” The Lancet, vol. 370, no. 9591, pp. 949–956, 2007. View at Publisher · View at Google Scholar · View at Scopus
  8. B. I. Eriksson, L. C. Borris, R. J. Friedman et al., “Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty,” The New England Journal of Medicine, vol. 358, no. 26, pp. 2765–2775, 2008. View at Publisher · View at Google Scholar · View at Scopus
  9. A. K. Kakkar, B. Brenner, O. E. Dahl et al., “Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial,” The Lancet, vol. 372, no. 9632, pp. 31–39, 2008. View at Publisher · View at Google Scholar · View at Scopus
  10. M. R. Lassen, W. Ageno, L. C. Borris et al., “Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty,” The New England Journal of Medicine, vol. 358, no. 26, pp. 2776–2786, 2008. View at Publisher · View at Google Scholar · View at Scopus
  11. A. G. Turpie, M. R. Lassen, B. L. Davidson et al., “Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial,” The Lancet, vol. 373, no. 9676, pp. 1673–1680, 2009. View at Publisher · View at Google Scholar · View at Scopus
  12. C. B. Granger, J. H. Alexander, J. J. McMurray et al., “Apixaban versus warfarin in patients with atrial fibrillation,” The New England Journal of Medicine, vol. 365, pp. 981–992, 2011. View at Google Scholar
  13. M. Barry, “Dabigatran versus warfarin in patients with atrial fibrillation,” The New England Journal of Medicine, vol. 361, no. 27, p. 2674, 2009. View at Google Scholar · View at Scopus
  14. M. R. Patel, K. W. Mahaffey, J. Garg et al., “Rivaroxaban versus warfarin in nonvalvular atrial fibrillation,” The New England Journal of Medicine, vol. 365, no. 10, pp. 883–891, 2011. View at Publisher · View at Google Scholar · View at Scopus
  15. E. Investigators, R. Bauersachs, S. D. Berkowitz et al., “Oral rivaroxaban for symptomatic venous thromboembolism,” The New England Journal of Medicine, vol. 363, pp. 2499–2510, 2010. View at Google Scholar
  16. H. R. Büller, M. H. Prins, A. W. A. Lensing et al., “Oral rivaroxaban for the treatment of symptomatic pulmonary embolism,” The New England Journal of Medicine, vol. 366, no. 14, pp. 1287–1297, 2012. View at Publisher · View at Google Scholar · View at Scopus
  17. J. Mega, E. Braunwald, S. Mohanavelu et al., “Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): a randomised, double-blind, phase II trial,” The Lancet, vol. 374, no. 9683, pp. 29–38, 2009. View at Publisher · View at Google Scholar · View at Scopus
  18. J. L. Mega, E. Braunwald, S. D. Wiviott et al., “Rivaroxaban in patients with a recent acute coronary syndrome,” The New England Journal of Medicine, vol. 366, pp. 9–19, 2012. View at Google Scholar
  19. E. M. Hylek, C. Held, J. H. Alexander et al., “Major bleeding in patients with atrial fibrillation receiving apixaban or warfarin in the ARISTOTLE trial: predictors, characteristics, and clinical outcomes,” Journal of the American College of Cardiology, 2014. View at Publisher · View at Google Scholar
  20. J. Harenberg, S. Marx, O. E. Dahl et al., “Interpretation of endpoints in a network meta-analysis of new oral anticoagulants following total hip or total knee replacement surgery,” Thrombosis and Haemostasis, vol. 108, pp. 903–912, 2012. View at Google Scholar
  21. M. R. Southworth, M. E. Reichman, and E. F. Unger, “Dabigatran and postmarketing reports of bleeding,” The New England Journal of Medicine, vol. 368, pp. 1272–1274, 2013. View at Google Scholar
  22. C. Frost, S. Nepal, J. Wang et al., “Safety, pharmacokinetics and pharmacodynamics of multiple oral doses of apixaban, a factor Xa inhibitor, in healthy subjects,” British Journal of Clinical Pharmacology, vol. 76, pp. 776–786, 2013. View at Google Scholar
  23. W. Mueck, J. Stampfuss, D. Kubitza, and M. Becka, “Clinical pharmacokinetic and pharmacodynamic profile of rivaroxaban,” Clinical Pharmacokinetics, vol. 53, pp. 1–16, 2014. View at Google Scholar
  24. J. Stangier and A. Clemens, “Pharmacology, pharmacokinetics, and pharmacodynamics of dabigatran etexilate, an oral direct thrombin inhibitor,” Clinical and Applied Thrombosis/Hemostasis, vol. 15, supplement 1, pp. 9S–16S, 2009. View at Google Scholar · View at Scopus
  25. A. Tamigniau, J. Douxfils, J. B. Nicolas et al., “Why, when and how to monitor new oral anticoagulants,” Revue Médicale Suisse, vol. 10, pp. 326–333, 2014. View at Google Scholar
  26. H. Heidbuchel, P. Verhamme, M. Alings et al., “European Heart Rhythm Association Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation,” Europace, vol. 15, pp. 625–651, 2013. View at Google Scholar
  27. E. Nutescu, I. Chuatrisorn, and E. Hellenbart, “Drug and dietary interactions of warfarin and novel oral anticoagulants: an update,” Journal of Thrombosis and Thrombolysis, vol. 31, no. 3, pp. 326–343, 2011. View at Publisher · View at Google Scholar · View at Scopus
  28. J. M. Walenga and C. Adiguzel, “Drug and dietary interactions of the new and emerging oral anticoagulants,” International Journal of Clinical Practice, vol. 64, no. 7, pp. 956–967, 2010. View at Publisher · View at Google Scholar · View at Scopus
  29. G. Pernod, P. Albaladejo, A. Godier et al., “Management of major bleeding complications and emergency surgery in patients on long-term treatment with direct oral anticoagulants, thrombin or factor-Xa inhibitors: proposals of the working group on perioperative haemostasis (GIHP)—March 2013,” Archives of Cardiovascular Diseases, vol. 106, pp. 382–393, 2013. View at Google Scholar
  30. R. De Caterina, S. Husted, L. Wallentin et al., “Vitamin K antagonists in heart disease: current status and perspectives (Section III). Position paper of the ESC Working Group on Thrombosis—task Force on Anticoagulants in Heart Disease,” Thrombosis and Haemostasis, vol. 110, pp. 1087–1107, 2013. View at Google Scholar
  31. L. Poller, J. Jespersen, S. Ibrahim, and A. Pattison, “European Action on A. Phase III studies on novel oral anticoagulants for stroke prevention in atrial fibrillation: a look beyond the excellent results: a rebuttal,” Journal of Thrombosis and Haemostasis, vol. 11, pp. 1203–1205, 2013. View at Google Scholar
  32. J. Desai, J. M. Kolb, J. I. Weitz, and J. Aisenberg, “Gastrointestinal bleeding with the new oral anticoagulants—defining the issues and the management strategies,” Thrombosis and Haemostasis, vol. 110, pp. 205–212, 2013. View at Google Scholar
  33. “Pradaxa-H-C-829-X-13: ePAR—assessment Report—extension,” 2011, http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Assessment_Report_-_Variation/human/000829/WC500110875.pdf.
  34. K. W. McConeghy, A. Bress, D. M. Qato, C. Wing, and E. A. Nutescu, “Evaluation of dabigatran bleeding adverse reaction reports in the FDA adverse event reporting system during the first year of approval,” Pharmacotherapy, 2014. View at Publisher · View at Google Scholar
  35. J. W. Eikelboom, L. Wallentin, S. J. Connolly et al., “Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) Trial,” Circulation, vol. 123, no. 21, pp. 2363–2372, 2011. View at Publisher · View at Google Scholar · View at Scopus
  36. K. Kirley, D. M. Qato, R. Kornfield, R. S. Stafford, and G. C. Alexander, “National trends in oral anticoagulant use in the United States, 2007 to 2011,” Circulation Cardiovascular Quality and Outcomes, vol. 5, pp. 615–621, 2012. View at Google Scholar
  37. S. L. Lim and E. Maxwell, “An audit of dabigatran etexilate prescribing in Victoria,” Medical Journal of Australia, vol. 198, pp. 314–315, 2013. View at Google Scholar
  38. R. Sorensen, G. Gislason, C. Torp-Pedersen et al., “Dabigatran use in Danish atrial fibrillation patients in 2011: a Nationwide Study,” BMJ Open, vol. 3, article e002758, 2013. View at Google Scholar
  39. B. Carley, S. Griesbach, T. Larson, and K. Krueger, “Assessment of dabigatran utilization and prescribing patterns for atrial fibrillation in a physician group practice setting,” The American Journal of Cardiology, vol. 113, pp. 650–654, 2014. View at Google Scholar
  40. C. Escobar and V. Barrios, “Dabigatran and bleeding risk: the importance of a correct prescription,” The Journal of Emergency Medicine, 2013. View at Publisher · View at Google Scholar
  41. A. Troncoso and E. Diogene, “Dabigatran and rivaroxaban prescription for atrial fibrillation in Catalonia, Spain: the need to manage the introduction of new drugs,” European Journal of Clinical Pharmacology, vol. 70, pp. 249–250, 2014. View at Google Scholar
  42. “European Medicine Agency—xarelto: summary of Product Characteristics,” 2013, http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000944/WC500057108.pdf.
  43. “European Medicine Agency—pradaxa: summary of Product Characteristics,” 2013, http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000829/WC500041059.pdf.
  44. “European Medicine Agency—eliquis: summary of Product Characteristics,” 2014, http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002148/WC500107728.pdf.
  45. W. Pfeilschifter, S. Luger, R. Brunkhorst, E. Lindhoff-Last, and C. Foerch, “The gap between trial data and clinical practice—an analysis of case reports on bleeding complications occurring under dabigatran and rivaroxaban anticoagulation,” Cerebrovascular Disease, vol. 36, pp. 115–119, 2013. View at Google Scholar
  46. A. Hellden, I. Odar-Cederlof, G. Nilsson et al., “Renal function estimations and dose recommendations for dabigatran, gabapentin and valaciclovir: a data simulation study focused on the elderly,” BMJ Open, vol. 3, article e002686, 2013. View at Google Scholar
  47. P. K. Maccallum, R. Mathur, S. A. Hull et al., “Patient safety and estimation of renal function in patients prescribed new oral anticoagulants for stroke prevention in atrial fibrillation: a Cross-Sectional Study,” BMJ Open, vol. 3, article e003343, 2013. View at Google Scholar
  48. K. Moore, S. Vaidyanathan, C. Damaraju, and L. Fields, “The relative bioavailability of single-dose rivaroxaban, a novel oral anticoagulant and a selective direct factor Xa inhibitor, administered orally (as a whole or crushed tablet) and via nasogastric tube (as a crushed tablet suspension),” Pharmacotherapy, vol. 32, article 2, 2012. View at Google Scholar
  49. J. P. Patel, L. N. Roberts, and R. Arya, “Anticoagulating obese patients in the modern era,” British Journal of Haematology, vol. 155, no. 2, pp. 137–149, 2011. View at Publisher · View at Google Scholar · View at Scopus
  50. “Pradaxa: full Prescribing Information,” 2013, http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/022512s017lbl.pdf.
  51. D. Kubitza, M. Becka, M. Zuehlsdorf, and W. Mueck, “Body weight has limited influence on the safety, tolerability, pharmacokinetics, or pharmacodynamics of rivaroxaban (BAY 59-7939) in healthy subjects,” Journal of Clinical Pharmacology, vol. 47, no. 2, pp. 218–226, 2007. View at Publisher · View at Google Scholar · View at Scopus
  52. W. Mueck, B. I. Eriksson, K. A. Bauer et al., “Population pharmacokinetics and pharmacodynamics of rivaroxaban—an oral, direct factor Xa inhibitor—in patients undergoing major orthopaedic surgery,” Clinical Pharmacokinetics, vol. 47, no. 3, pp. 203–216, 2008. View at Publisher · View at Google Scholar · View at Scopus
  53. V. V. Upreti, J. Wang, Y. C. Barrett et al., “Effect of extremes of body weight on the pharmacokinetics, pharmacodynamics, safety and tolerability of apixaban in healthy subjects,” British Journal of Clinical Pharmacology, vol. 76, pp. 908–916, 2013. View at Google Scholar
  54. “Food and Drug Administration—eliquis: full Prescribing Information,” 2014, http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/202155s000lbl.pdf.
  55. “Food and drug Administration—eliquis: clinical Pharmacology & Biopharmaceutical Review(s),” 2014, http://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202155Orig1s000ClinPharmR.pdf.
  56. J. Stangier, H. Stähle, K. Rathgen, W. Roth, and K. Shakeri-Nejad, “Pharmacokinetics and pharmacodynamics of dabigatran etexilate, an oral direct thrombin inhibitor, are not affected by moderate hepatic impairment,” Journal of Clinical Pharmacology, vol. 48, no. 12, pp. 1411–1419, 2008. View at Publisher · View at Google Scholar · View at Scopus
  57. J. Graff and S. Harder, “Anticoagulant therapy with the oral direct factor Xa inhibitors rivaroxaban, apixaban and edoxaban and the thrombin inhibitor dabigatran etexilate in patients with hepatic impairment,” Clinical Pharmacokinetics, vol. 52, pp. 243–254, 2013. View at Google Scholar
  58. D. Kubitza, A. Roth, M. Becka et al., “Effect of hepatic impairment on the pharmacokinetics and pharmacodynamics of a single dose of rivaroxaban, an oral, direct Factor Xa inhibitor,” British Journal of Clinical Pharmacology, vol. 76, pp. 89–98, 2013. View at Google Scholar
  59. C. E. Frost, Z. Yu, J. Wang et al., “Single-dose safety and pharmacokinetics of apixaban in subjects with mild or moderate hepatic impairment,” Clinical Pharmacology & Therapeutics, vol. 85, supplement 1, article PI-84, p. S34, 2009. View at Google Scholar
  60. F. Rodeghiero, A. Tosetto, T. Abshire et al., “ISTH/SSC bleeding assessment tool: a standardized questionnaire and a proposal for a new bleeding score for inherited bleeding disorders,” Journal of Thrombosis and Haemostasis, vol. 8, no. 9, pp. 2063–2065, 2010. View at Publisher · View at Google Scholar · View at Scopus
  61. S. Apostolakis, D. A. Lane, H. Buller, and G. Y. Lip, “Comparison of the CHADS2, CHA2DS2-VASc and HAS-BLED scores for the prediction of clinically relevant bleeding in anticoagulated patients with atrial fibrillation: the AMADEUS trial,” Thrombosis and Haemostasis, vol. 110, pp. 1074–1079, 2013. View at Google Scholar
  62. S. Burgess, N. Crown, M. L. Louzada, G. Dresser, R. B. Kim, and A. Lazo-Langner, “Clinical performance of bleeding risk scores for predicting major and clinically relevant non-major bleeding events in patients receiving warfarin,” Journal of Thrombosis and Haemostasis, vol. 11, pp. 1647–1654, 2013. View at Google Scholar
  63. P. A. Reilly, T. Lehr, S. Haertter et al., “The effect of dabigatran plasma concentrations and patient characteristics on the frequency of ischemic stroke and major bleeding in atrial fibrillation patients: the RE-LY Trial (Randomized Evaluation of Long-Term Anticoagulation Therapy),” Journal of the American College of Cardiology, vol. 63, pp. 321–328, 2014. View at Google Scholar
  64. H. Ten Cate, “Monitoring new oral anticoagulants, managing thrombosis, or both?” Thrombosis and Haemostasis, vol. 107, no. 5, pp. 803–805, 2012. View at Publisher · View at Google Scholar · View at Scopus
  65. K.-H. Liesenfeld, T. Lehr, C. Dansirikul et al., “Population pharmacokinetic analysis of the oral thrombin inhibitor dabigatran etexilate in patients with non-valvular atrial fibrillation from the RE-LY trial,” Journal of Thrombosis and Haemostasis, vol. 9, no. 11, pp. 2168–2175, 2011. View at Publisher · View at Google Scholar · View at Scopus
  66. G. Freyburger, G. MacOuillard, S. Labrouche, and F. Sztark, “Coagulation parameters in patients receiving dabigatran etexilate or rivaroxaban: two observational studies in patients undergoing total hip or total knee replacement,” Thrombosis Research, vol. 127, no. 5, pp. 457–465, 2011. View at Publisher · View at Google Scholar · View at Scopus
  67. H. Mani and E. Lindhoff-Last, “Main considerable factors for correct laboratory test interpretation under DOA treatment,” Thrombosis Journal, vol. 11, article 22, 2013. View at Google Scholar
  68. M. M. Samama, “Coagulation Assays in Patients with New Oral Anticoagulants (NOACs): why? When?” Drug Development Research, vol. 74, article 7, 2013. View at Google Scholar
  69. H. Ten Cate, “New oral anticoagulants: discussion on monitoring and adherence should start now!,” Thrombosis Journal, vol. 11, article 8, 2013. View at Google Scholar
  70. T. Baglin, D. Keeling, and S. Kitchen, “Effects on routine coagulation screens and assessment of anticoagulant intensity in patients taking oral dabigatran or rivaroxaban: guidance from the British Committee for Standards in Haematology,” British Journal of Haematology, vol. 159, pp. 427–429, 2012. View at Google Scholar
  71. A. G. Turpie, R. Kreutz, J. Llau, B. Norrving, and S. Haas, “Management consensus guidance for the use of rivaroxaban—an oral, direct factor Xa inhibitor,” Thrombosis and Haemostasis, vol. 108, pp. 876–886, 2012. View at Google Scholar
  72. T. Baglin, A. Hillarp, A. Tripodi, I. Elalamy, H. Buller, and W. Ageno, “Measuring Oral Direct Inhibitors (ODIs) of thrombin and factor Xa: a recommendation from the Subcommittee on Control of Anticoagulation of the Scientific and Standardisation Committee of the International Society on Thrombosis and Haemostasis,” Journal of Thrombosis and Haemostasis, 2013. View at Publisher · View at Google Scholar
  73. Y. C. Barrett, J. Wang, Y. Song et al., “A randomised assessment of the pharmacokinetic, pharmacodynamic and safety interaction between apixaban and enoxaparin in healthy subjects,” Thrombosis and Haemostasis, vol. 107, no. 5, pp. 916–924, 2012. View at Publisher · View at Google Scholar · View at Scopus
  74. J. Douxfils, F. Mullier, S. Robert, C. Chatelain, B. Chatelain, and J.-M. Dogné, “Impact of dabigatran on a large panel of routine or specific coagulation assays: laboratory recommendations for monitoring of dabigatran etexilate,” Thrombosis and Haemostasis, vol. 107, no. 5, pp. 985–997, 2012. View at Publisher · View at Google Scholar · View at Scopus
  75. J. Douxfils, C. Chatelain, B. Chatelain, J.-M. Dogné, and F. Mullier, “Impact of apixaban on routine and specific coagulation assays: a practical laboratory guide,” Thrombosis and Haemostasis, vol. 110, pp. 283–294, 2013. View at Google Scholar
  76. J. Douxfils, A. Tamigniau, B. Chatelain et al., “Comparison of calibrated chromogenic anti-Xa assay and PT tests with LC-MS/MS for the therapeutic monitoring of patients treated with rivaroxaban,” Thrombosis and Haemostasis, vol. 110, pp. 723–731, 2013. View at Google Scholar
  77. M. V. Huisman, G. Y. H. Lip, H.-C. Diener, M. Brueckmann, J. Van Ryn, and A. Clemens, “Dabigatran etexilate for stroke prevention in patients with atrial fibrillation: resolving uncertainties in routine practice,” Thrombosis and Haemostasis, vol. 107, no. 5, pp. 838–847, 2012. View at Publisher · View at Google Scholar · View at Scopus
  78. T. H. Baron, P. S. Kamath, and R. D. McBane, “Management of antithrombotic therapy in patients undergoing invasive procedures,” The New England Journal of Medicine, vol. 368, pp. 2113–2124, 2013. View at Google Scholar
  79. S. A. Kozek-Langenecker, “Perioperative management issues of direct oral anticoagulants,” Seminars in Hematology, 2014. View at Publisher · View at Google Scholar
  80. A. Liew and J. Douketis, “Perioperative management of patients who are receiving a novel oral anticoagulant,” Internal and Emergency Medicine, vol. 8, pp. 477–484, 2013. View at Google Scholar
  81. P. Sié, C. M. Samama, A. Godier et al., “Surgery and invasive procedures in patients on long-term treatment with direct oral anticoagulants: thrombin or factor-Xa inhibitors. Recommendations of the Working Group on perioperative haemostasis and the French Study Group on thrombosis and haemostasis,” Archives of Cardiovascular Diseases, vol. 104, no. 12, pp. 669–676, 2011. View at Publisher · View at Google Scholar · View at Scopus
  82. A. C. Spyropoulos and J. D. Douketis, “How I treat anticoagulated patients undergoing an elective procedure or surgery,” Blood, vol. 120, pp. 2954–2962, 2012. View at Google Scholar
  83. J. Beyer-Westendorf, V. Gelbricht, K. Forster et al., “Peri-interventional management of novel oral anticoagulants in daily care: results from the prospective Dresden NOAC registry,” European Heart Journal, 2014. View at Publisher · View at Google Scholar
  84. W. Gogarten, E. Vandermeulen, H. Van Aken, S. Kozek, J. V. Llau, and C. M. Samama, “Regional anaesthesia and antithrombotic agents: recommendations of the European Society of Anaesthesiology,” European Journal of Anaesthesiology, vol. 27, no. 12, pp. 999–1015, 2010. View at Publisher · View at Google Scholar · View at Scopus
  85. J. H. Levy, D. Faraoni, J. L. Spring, J. D. Douketis, and C. M. Samama, “Managing new oral anticoagulants in the perioperative and intensive care unit setting,” Anesthesiology, vol. 118, pp. 1466–1474, 2013. View at Google Scholar
  86. J. V. Llau and R. Ferrandis, “New anticoagulants and regional anesthesia,” Current Opinion in Anaesthesiology, vol. 22, no. 5, pp. 661–666, 2009. View at Publisher · View at Google Scholar · View at Scopus
  87. N. Rosencher, M.-P. Bonnet, and D. I. Sessler, “Selected new antithrombotic agents and neuraxial anaesthesia for major orthopaedic surgery: management strategies,” Anaesthesia, vol. 62, no. 11, pp. 1154–1160, 2007. View at Publisher · View at Google Scholar · View at Scopus
  88. S. Kaatz and M. Crowther, “Reversal of target-specific oral anticoagulants,” Journal of Thrombosis and Thrombolysis, vol. 36, pp. 195–202, 2013. View at Google Scholar
  89. S. Kaatz, P. A. Kouides, D. A. Garcia et al., “Guidance on the emergent reversal of oral thrombin and factor Xa inhibitors,” American Journal of Hematology, vol. 87, no. 1, pp. S141–S145, 2012. View at Publisher · View at Google Scholar · View at Scopus
  90. D. M. Siegal, D. A. Garcia, and M. A. Crowther, “How I treat target-specific oral anticoagulant-associated bleeding,” Blood, vol. 123, pp. 1152–1158, 2014. View at Google Scholar
  91. A. Majeed, H. G. Hwang, S. J. Connolly et al., “Management and outcomes of major bleeding during treatment with dabigatran or warfarin,” Circulation, vol. 128, pp. 2325–2332, 2013. View at Google Scholar
  92. G. Dickneite and M. Hoffman, “Reversing the new oral anticoagulants with prothrombin complex concentrates (PCCs): what is the evidence?” Thrombosis and Haemostasis, vol. 111, pp. 189–198, 2014. View at Google Scholar
  93. J. P. Piccini, J. Garg, M. R. Patel et al., “Management of major bleeding events in patients treated with rivaroxaban vs. warfarin: results from the ROCKET AF trial,” European Heart Journal, 2014. View at Publisher · View at Google Scholar
  94. J. Van Ryn, J. Stangier, S. Haertter et al., “Dabigatran etexilate—a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity,” Thrombosis and Haemostasis, vol. 103, no. 6, pp. 1116–1127, 2010. View at Publisher · View at Google Scholar · View at Scopus
  95. M. R. Wanek, E. T. Horn, S. Elapavaluru, S. C. Baroody, and G. Sokos, “Safe use of hemodialysis for dabigatran removal before cardiac surgery,” Annals of Pharmacotherapy, vol. 46, article e21, 2012. View at Google Scholar
  96. T. E. Warkentin, P. Margetts, S. J. Connolly, A. Lamy, C. Ricci, and J. W. Eikelboom, “Recombinant factor VIIa (rFVIIa) and hemodialysis to manage massive dabigatran-associated postcardiac surgery bleeding,” Blood, vol. 119, no. 9, pp. 2172–2174, 2012. View at Publisher · View at Google Scholar · View at Scopus
  97. O. Grottke, J. van Ryn, H. M. Spronk, and R. Rossaint, “Prothrombin complex concentrates and a specific antidote to dabigatran are effective ex-vivo in reversing the effects of dabigatran in an anticoagulation/liver trauma experimental model,” Critical Care, vol. 18, article R27, 2014. View at Google Scholar
  98. G. Lu, F. R. DeGuzman, S. J. Hollenbach et al., “A specific antidote for reversal of anticoagulation by direct and indirect inhibitors of coagulation factor Xa,” Nature Medicine, vol. 19, pp. 446–451, 2013. View at Google Scholar
  99. C. Ward, G. Conner, G. Donnan, A. Gallus, and S. McRae, “Practical management of patients on apixaban: a consensus guide,” Thrombosis Journal, vol. 11, article 27, 2013. View at Google Scholar
  100. A. Majeed and S. Schulman, “Bleeding and antidotes in new oral anticoagulants,” Best Practice & Research Clinical Haematology, vol. 26, pp. 191–202, 2013. View at Google Scholar